Dashboard
Manage Tickers

ENSC Ensysce Biosciences, Inc.

Nasdaq ensysce.com


$ 2.03 $ -0.01 (-0.48 %)    

Friday, 14-Nov-2025 15:53:53 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 2.06
$ 2.04
$ 2.03 x 284
$ 2.09 x 100
$ 2.04 - $ 2.15
$ 1.62 - $ 11.13
65,859
na
7.3M
$ 2.37
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-10-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-10-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 06-08-2021 03-31-2021 10-Q
20 03-15-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-07-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-10-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 03-11-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-01-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 03-09-2018 12-31-2017 10-K
33 01-09-2018 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ensysce-biosciences-q3-eps-129-misses-084-estimate-sales-493104k-miss-700000k-estimate
Ensysce Biosciences Q3 EPS $(1.29) Misses ...
11/14/2025 21:18:41

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
10/13/2025 12:08:59

ensysce-biosciences-showcases-taap-and-mpar-platforms-in-painweek2025-symposium-highlights-redefining-opioid-safety-amid-global-crisis
Ensysce Biosciences Showcases TAAP and MPA...
10/10/2025 12:17:31

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company p...

ensysce-biosciences-q2-eps-079-beats-118-estimate-sales-1371m-beat-650000k-estimate
Ensysce Biosciences Q2 EPS $(0.79) Beats $...
08/13/2025 20:20:52

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 12:08:18

ensysce-biosciences-receives-fda-feedback-on-development-of-pf614-mpar-says-meeting-confirmed-pf614-mpar-may-be-eligible-to-pursue-streamlined-505b2-regulatory-pathway
Ensysce Biosciences Receives FDA Feedback ...
07/31/2025 12:05:48

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/23/2025 12:08:15

watching-ensysce-biosciences-zacks-small-cap-research-reiterates-1845-price-valuation-was-originally-given-on-may-14-2025
Watching Ensysce Biosciences; Zacks Small-...
07/16/2025 15:06:39

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07162025_ENSC_Sorensen.pdf

ensysce-biosciences-launches-phase-3-trial-for-abuse-resistant-painkiller-pf614-selects-rho-inc-as-clinical-partner
Ensysce Biosciences Launches Phase 3 Trial...
07/16/2025 12:05:22

~ FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~SAN DIEGO, CA / ACCESS Newswire / July 16, ...

ensysce-biosciences-says-it-fully-enrolled-part-2-of-critical-three-part-pf614-mpar-102-clinical-study-to-study-effect-of-food-on-mpar-technology
Ensysce Biosciences Says It Fully Enrolled...
06/24/2025 12:11:46

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~~ Grant Funds from NIDA Accelerating Clinical Developmen...

ensysce-biosciences-secures-53m-in-continued-nida-support-to-advance-opioid-overdose-protection
Ensysce Biosciences Secures $5.3M In Conti...
06/04/2025 12:13:08

~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~~ Funds Accelerate Path Towards Commercialization ~

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
05/16/2025 21:05:51

watching-ensysce-biosciences-zacks-small-cap-research-gives-stock-1845-price-valuation
Watching Ensysce Biosciences; Zacks Small-...
05/14/2025 15:04:22

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_05142025_ENSC_Sorensen.pdf

ensysce-biosciences-q1-eps-139-beats-302-estimate-sales-132m-up-from-30572k-yoy
Ensysce Biosciences Q1 EPS $(1.39) Beats $...
05/13/2025 20:39:17

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
04/24/2025 17:05:54

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
04/24/2025 12:06:59

why-servicenow-shares-are-trading-higher-by-9-here-are-20-stocks-moving-premarket
Why ServiceNow Shares Are Trading Higher B...
04/24/2025 09:30:36

ensysce-biosciences-stock-doubles-in-one-trading-session---heres-why
Ensysce Biosciences Stock Doubles In One T...
04/23/2025 21:11:43

Ensysce Biosciences rises after patent notice for PF9001, a methadone prodrug aimed at safer opioid use with overdose protectio...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
04/23/2025 21:05:54

ensysce-biosciences-to-exercise-certain-outstanding-warrants-to-purchase-up-to-an-aggregate-of-630376-shares-of-common-stock-of-the-company-originally-issued-in-march-2025-having-an-exercise-price-of-324-per-share
Ensysce Biosciences To Exercise Certain Ou...
04/23/2025 20:46:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION